Topical Collection "Positron Emission Tomography (PET) in Oncology"


A topical collection in Diagnostics (ISSN 2075-4418).


Collection Editor
Dr. Annika Loft
Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark
Interests: PET; PET/CT; oncology

Topical Collection Information

Dear Colleagues,

Positron emission tomography (PET) has been called “the fastest growing medical technology ever”. Regardless of whether this is absolutely true, there is no doubt that PET has dramatically changed the handling of many cancer patients.
PET has in different cancer forms proved to be excellent for diagnosing, staging and treatment monitoring. FDG-PET has strong prognostic value and may be used for tailoring therapy including external radiation.
Accordingly, decades of evaluation and research of mainly FDG-PET has established this as a powerful tool in cancer patients. However, this may only be the beginning of the PET era since the concept of molecular imaging with use of different PET tracers for tissue characterization in cancer may very well be what is needed to make the paradigm of tailored therapy come true.
This collection invites all types of submission on use of PET in cancer. Both experimental, preclinical and clinical papers are welcome.

Dr. Annika Loft
Collection Editor

Manuscript Submission Information

Manuscripts for the topical collection can be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on this website. The topical collection considers regular research articles, short communications and review articles. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page.

Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.


  • positron emission tomography
  • oncology
  • cancer
  • tailored therapy
  • diagnosis
  • staging
  • response monitoring

Published Papers

No papers have been published in this collection yet, see below for planned papers.

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Positron Emission Tomography in Breast Cancer
Authors: Jose Luis Vercher-Conejero, Laura Pelegrí-Martinez, Diego Lopez-Aznar and
María del Puig Cózar-Santiago
Abstract: Gradually, FDG-PET/CT has been strengthening within the diagnostic algorithms of oncological diseases. In many of these, PET/CT has shown to be useful at different stages of the disease: diagnosis, staging or re-staging, treatment response assessment, and recurrence. Some of the advantages of this imaging modality versus CT, MRI, bone scan, mammography or ultrasound, are based on its great diagnostic capacity since, according to the radiopharmaceutical used, reflects metabolic changes that often occur before morphological changes and therefore allows us to stage at diagnosis. Moreover, another advantage of this technique is that it allows us to evaluate the whole body so it can be very useful for the detection of distant disease. With regard to breast cancer, FDG-PET/CT has proven to be important when recurrence is suspected or in the evaluation of treatment response. The technological advancement of PET equipment through the development of new detectors and equipment designed specifically for breast imaging, and the development of more specific radiopharmaceuticals for the study of the different biological processes of breast cancer, will allow progress not only in the diagnosis of the disease being even more precocious but also will enable personalized therapy in patients with breast cancer.

Last update: 16 January 2015

Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert